keyword
MENU ▼
Read by QxMD icon Read
search

Dasotraline

keyword
https://www.readbyqxmd.com/read/26794682/assessment-of-human-abuse-potential-of-dasotraline-compared-to-methylphenidate-and-placebo-in-recreational-stimulant-users
#1
RANDOMIZED CONTROLLED TRIAL
K S Koblan, S C Hopkins, K Sarma, N Gallina, F Jin, N Levy-Cooperman, K A Schoedel, A Loebel
AIMS: The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD). METHODS: Recreational stimulant users (N=48) who had specific experience with cocaine, and who were able to distinguish methylphenidate (60 mg) versus placebo in a qualification session, were randomized, in a 6-period, double-blind, crossover design, to receive single doses of dasotraline 8 mg, 16 mg, and 36 mg, methylphenidate (MPH) 40 mg and 80 mg, and placebo...
February 1, 2016: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/26597180/pharmacokinetics-and-exposure-response-relationships-of-dasotraline-in-the-treatment-of-attention-deficit-hyperactivity-disorder-in-adults
#2
Seth C Hopkins, Soujanya Sunkaraneni, Estela Skende, Jeremy Hing, Julie A Passarell, Antony Loebel, Kenneth S Koblan
BACKGROUND AND OBJECTIVES: Dasotraline is a novel inhibitor of dopamine and norepinephrine reuptake currently being investigated in clinical studies for the treatment of attention-deficit/hyperactivity disorder (ADHD). Uniquely, relative to current ADHD medications, dasotraline has a slow absorption and long elimination half-life. Here we relate the pharmacokinetics and pharmacodynamics of dasotraline to reduction in ADHD symptoms based on simulated clinical trial outcomes. METHODS: Dasotraline pharmacokinetics were analyzed by population pharmacokinetic methodologies using data collected from 395 subjects after single or multiple oral dose administrations ranging from 0...
February 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/25948101/dasotraline-for-the-treatment-of-attention-deficit-hyperactivity-disorder-a-randomized-double-blind-placebo-controlled-proof-of-concept-trial-in-adults
#3
RANDOMIZED CONTROLLED TRIAL
Kenneth S Koblan, Seth C Hopkins, Kaushik Sarma, Fengbin Jin, Robert Goldman, Scott H Kollins, Antony Loebel
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity associated with clinically significant impairment in functioning. ADHD has an early onset, but frequently persists, with a prevalence estimate of 4% in adults. Dasotraline is a novel compound that is a potent inhibitor of dopamine and norepinephrine transporters that achieves stable plasma concentrations with once-daily dosing. In this study, adult outpatients meeting DSM-IV-TR criteria for ADHD were randomized to 4 weeks of double-blind, once-daily treatment with dasotraline 4 and 8 mg/day or placebo...
November 2015: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"